丨 2025年3月5日星期三丨 NO.1 复星医药子公司疫苗获批临床 复星医药控股子公司复星安特金(成都)生物制药有限公司于近日收到国家药品监督管理局关于24价肺炎球菌多糖结合疫苗的临床试验批准。复星安特金拟于条件具备后开展该疫苗的I期临床试验。 点评:截至本公告披露日,全球范围内尚无24价肺炎球菌多糖结合疫苗获批上市。该疫苗有望进一步丰富肺炎预防产品线,提升公司在疫苗领域的竞争力。若...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.